Search

Your search keyword '"Mousset, Sabine"' showing total 9 results
Start Over Author "Mousset, Sabine" Search Limiters Available in Library Collection
9 results on '"Mousset, Sabine"'

1. Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell Transplant Centers

Author

Wolff, Daniel, Ayuk, Francis, Elmaagacli, Ahmet, Bertz, Hartmut, Lawitschka, Anita, Schleuning, Michael, Meyer, Ralf-Georg, Gerbitz, Armin, Hilgendorf, Inken, Hildebrandt, Gerhard C., Edinger, Matthias, Klein, Stephan, Halter, Jörg, Mousset, Sabine, Holler, Ernst, and Greinix, Hildegard T.

Published
2013
Full Text
View/download PDF

2. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens

Author

Rickerts, Volker, Mousset, Sabine, Lambrecht, Evelyn, Tintelnot, Kathrin, Schwerdtfeger, Rainer, Presterl, Elisabeth, Jacobi, Volkmar, Just-Nubling, Gudrun, and Bialek, Ralf

Subjects
Mycoses -- Diagnosis, Molds (Fungi) -- Identification and classification, Polymerase chain reaction -- Analysis, Tissue culture -- Analysis, Microbiological assay -- Analysis, Health, Health care industry
Published
2007

3. Treatment of invasive fungal infections in cancer patients : updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Mousset, Sabine, Buchheidt, Dieter, Heinz, Werner, Ruhnke, Markus, Cornely, Oliver Andreas, Egerer, Gerlinde, Krüger, William, Link, Hartmut, Neumann, Silke, Ostermann, Helmut, Panse, Jens, Penack, Olaf, Rieger, Christina, Schmidt-Hieber, Martin, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew J., Wolf, Hans-Heinrich, Maschmeyer, Georg, and Böhme, Angelika

Subjects
ddc:610
Abstract

The Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) here presents its updated recommendations for the treatment of documented fungal infections. Invasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. In recent years, new antifungal agents have been licensed, and agents already approved have been studied in new indications. The choice of the most appropriate antifungal treatment depends on the fungal species suspected or identified, the patient’s risk factors (e.g., length and depth of neutropenia), and the expected side effects. This guideline reviews the clinical studies that served as a basis for the following recommendations. All recommendations including the levels of evidence are summarized in tables to give the reader rapid access to the information.

Published
2013

9. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents.

Author

Schmidt-Hieber M, Schwender J, Heinz WJ, Zabelina T, Kühl JS, Mousset S, Schüttrumpf S, Junghanss C, Silling G, Basara N, Neuburger S, Thiel E, and Blau IW

Subjects
Adolescent, Adult, Aged, Alemtuzumab, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm therapeutic use, Antineoplastic Agents therapeutic use, Antiviral Agents therapeutic use, Child, Child, Preschool, Combined Modality Therapy, Encephalitis, Viral drug therapy, Female, Hematologic Neoplasms therapy, Humans, Immunosuppressive Agents therapeutic use, Infant, Lymphocyte Depletion, Male, Middle Aged, Muromonab-CD3 therapeutic use, Retrospective Studies, Survival Rate, Transplantation, Homologous, Treatment Outcome, Virus Activation, Young Adult, Encephalitis, Viral etiology, Graft vs Host Disease etiology, Hematopoietic Stem Cell Transplantation adverse effects
Abstract

Background: Limited data are available on characteristics of viral encephalitis in patients after allogeneic stem cell transplantation., Design and Methods: We analyzed 2,628 patients after allogeneic stem cell transplantation to identify risk factors and characteristics of viral encephalitis., Results: Viral encephalitis occurred in 32 patients (1.2%, 95% confidence interval 0.8%-1.6%) and was associated with the use of OKT-3 or alemtuzumab for T-cell depletion (P < 0.001) and an increased mortality (P = 0.011) in comparison to patients without viral encephalitis. Detected viruses included human herpesvirus-6 (28%), Epstein-Barr virus (19%), herpes simplex virus (13%), JC virus (9%), varicella zoster virus (6%), cytomegalovirus (6%) and adenovirus (3%). More than one virus was identified in 16% of the patients. The median onset time was 106 days after allogeneic stem cell transplantation for the total group of 32 patients, but onset times were shortest in those with human herpesvirus-6 encephalitis and longest in those with JC virus-associated progressive multifocal leukoencephalopathy. The probability of a sustained response to treatment was 63% (95% confidence interval 44%-82%) with a median survival of 94 (95% confidence interval 36-152) days after onset, but significant variation was found when considering different causative viruses. Patients with herpes simplex virus encephalitis had the most favorable outcome with no encephalitis-related deaths., Conclusions: The use of OKT-3 or alemtuzumab for in vivo T-cell depletion is associated with an increased risk of viral encephalitis after allogeneic stem cell transplantation. Different viruses are frequently associated with distinct characteristics such as onset time, response to treatment and outcome.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results